News | April 04, 2011| Dave Fornell

Antioxidant Formula Prior to Radiation Exposure May Prevent DNA Injury

April 4, 2011 – A unique formulation of antioxidants taken orally before imaging with ionizing radiation minimizes cell damage, noted researchers at the Society of Interventional Radiology’s 36th Annual Scientific Meeting in Chicago. In what the researchers say is the first clinical trial of its kind, as much as a 50 percent reduction in DNA injury was observed after administering the formula prior to CT scans.

“In our initial small study, we found that pre-administering to patients a proprietary antioxidant formulation resulted in a notable dose-dependent reduction in DNA injury,” said Kieran J. Murphy, M.D., FSIR, professor and vice chair, director of research and deputy chief of radiology at the University of Toronto and University Health Network, Toronto, Canada. “This could play an important role in protecting adults and children who require imaging or a screening study.”

“Pre-administering this formula before a medical imaging exam may be one of the most important tools to provide radioprotection and especially important for patients in the getting CT scans,” said Murphy. The study’s data support the theory about a protective effect during these kinds of exposure.

“There is currently a great deal of controversy in determining the cancer risks associated with medical imaging exams. Although imaging techniques, such as CT scans and mammograms, provide crucial and often life-saving information to doctors and patients, they work by irradiating people with X-rays, and there is some evidence that these can, in the long run, cause cancer,” explained Murphy. The researchers responded to this patient need by exploring a way to protect individuals from these potentially harmful effects. This may be of importance to interventional and diagnostic radiologists and X-ray technologists who have occupational exposure also.

The small study showed that even though many antioxidants are poorly absorbed by the body, one particular mixture was effective in protecting against the specific type of injury caused by medical imaging exams. People are 70 percent water, and X-rays collide with water molecules to produce free radicals. These groups of atoms with an unpaired number of electrons are dangerous when they react with cellular components, causing damage and even cell death. Free radicals can go on to do damage by directly ionizing DNA and other cellular targets. The research team evaluated whether a special combination of antioxidants have an ability to neutralize these free radicals before they can do damage.

“Our intent was to develop an effective proprietary formula of antioxidants to be taken orally prior to exposure that can protect a patient’s DNA against free radical mediated radiation injury, and we have applied to patent this formulation and a specific dose strategy,” said Murphy.

The experiments measured DNA damage as a surrogate marker for DNA injury. Blood was drawn from two study volunteers in duplicate, creating four individual tests per data point. DNA strand breaks are repaired by a big protein complex that binds to the site of the damage. The researchers labeled one of the proteins with a fluorescent tag. Then, under a powerful 3-D microscope, the DNA is examined for signs of repair. The more repair that is seen, the more DNA damage must have been done by the CT scan to initiate that repair. The experiments showed a reduction of DNA repair in the treatment group, which means that there was less DNA injury as a result of pre-administering the antioxidant mixture.

The researchers concede that this is a small study and that a lot more research needs to be done. However, these initial results point toward a positive future for this kind of treatment. The group says the next step is a clinical trial in Toronto.

For more information: www.SIRweb.org

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Hitachi Supria True64 CT Receives FDA Clearance
Technology | Computed Tomography (CT)| September 15, 2017
Hitachi Healthcare Americas Inc. announced it has attained U.S. Food and Drug Administration (FDA) 510(k) clearance to...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init